Anavex Soars on Positive Alzheimer’s Results
Anavex Life Sciences was one of the stocks helping to prop up the market in Monday’s session.
Anavex Life Sciences was one of the stocks helping to prop up the market in Monday’s session.
Clearside Biomedical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
A new RBC report focuses on top biotech stocks with key data readouts coming in 2016. These three seem to be the farthest along and offer the best chance for approval.
Affymetrix was absolutely soaring early on Monday on word that it will be acquired. Thermo Fisher Scientific is the buyer.
Athersys has announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments.
Ardelyx recently filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
One good plan for stockholders who are seeing gains evaporate is to rotate to a more defensive sector. Large cap pharmaceutical stocks totally fit the bill.
Collegium Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.
Jaguar Animal Health has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny. These four companies with promising candidates all have dates with the agency this year.
Dynavax Technologies led the bulls on Thursday with positive results from a late stage clinical trial, on another consecutive down day for the broad markets.
Visterra has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case for each in 2016.
The U.S. Securities and Exchange Commission (SEC) has received a filing from Tabula Rasa HealthCare regarding its initial public offering (IPO).
Exelixis Inc. (NASDAQ: EXEL) was up slightly in Tuesday’s trading session following positive results from a late stage trial. The company announced the presentation of positive data from subgroup analyses of METEOR, the Phase…